{"id":924778,"date":"2026-01-07T08:27:17","date_gmt":"2026-01-07T13:27:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/"},"modified":"2026-01-07T08:27:17","modified_gmt":"2026-01-07T13:27:17","slug":"protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/","title":{"rendered":"Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NEW YORK, Jan.  07, 2026  (GLOBE NEWSWIRE) &#8212; Protara Therapeutics, Inc.<strong>\u00a0<\/strong>(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced\u00a0that management will present at the 44<sup>th<\/sup> Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 pm PT in San Francisco.<\/p>\n<p>A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company\u2019s website:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xLE59GzT9oJkUzmB9utgrNJ4eelWrbCqdWsrjjRTjJFk1G4ZVAin2p1zZQRk7pUO7p9y9sjTkDJyiAahi_z5Ub9XDsd5naT9U1uEdpqLmGY=\" rel=\"nofollow\" target=\"_blank\">https:\/\/ir.protaratx.com<\/a>. The webcast will be archived for a limited time following the presentation.<\/p>\n<p>\n        <strong>About\u00a0Protara Therapeutics, Inc.<\/strong>\n      <\/p>\n<p>Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara\u2019s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing\u00a0Phase 2\u00a0trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or na\u00efve to treatment with Bacillus Calmette-Gu\u00e9rin, as well as a\u00a0Phase 2\u00a0trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_PRer-c_tKi3FMu3eGaBvuvWUvYDbMAQ4orVUFQsSqclgyrcmJK2FCDfYdpkzejsBZLJLlJn3jQPS09Fa9kb-9LxXi0jzm1i8UbljBPFCHg47qOOomu-Zd9OSI8uoxK5QL2xbFQE2LoFHESyiCA72OeVH427m8ATWmdNXd4vPKnacOhR21Z0yDTkQnV1h2g_SlqI9y_ulhexsA0sfbgc1WpyAKfgSYu8KmvBEP5QoTO1KBsF5u-_pf0PRRF-6uoXwbi4iT-Kmq5svqToQa2ExqCv8QcacNHFyYXPx4fYVDd6foW3rK4KOT65ZnJwGZLPyKbboRQ6zOEsLb4DcKOj-VE9RYf605VafwaYZVe_ilgleNlq3WKF-EWYp6q6mZD5a0sYv9hodX4ZuT-4GF8MPY2A2AdpwCh7QwmhbckxmO1P0-EtA5lEqE5oUFRWbukvXZfEjONKMZA1S7x-e-hfP7X_Pjh7lJYEWKpr948vLtCeY6JOwjLk-uyJyZbuPqQrtpzQfkLV22TqrafliJGB-beriUzkZLW0QVUT_kUuN5MnXTxdGn_rZDvVz28pmZr9guF3RxRXUYO6As8leDSq2qieKCQYrJ7_tQ7RIKwGricRpnHev5A7dyDFYOpqlugq7KcOqN-x-E5jtcErpB8ak_Sb4Edn3rrVkkiDN39XIqVBXCdlLaPPg09smEERPBaEEAUoyZh5i8NP-1oek2aoBex8ugHmcPVYFYBYCVd8y7JBZTbQ4ifuEKS4i5ixESjYg3DRCB3lcoHsRE0E93WIHw==\" rel=\"nofollow\" target=\"_blank\">www.protaratx.com<\/a>.<\/p>\n<p>Company Contact:<\/p>\n<p>Justine O&#8217;Malley<br \/>Protara Therapeutics<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bRn7Pq92gaqQCjHv9tupgskeHyZAAypn_23dNp9uzZxykg6V8drZt-nLWftkRt1iCl3LyQ1PSuIjayCR1_x-mtN_Z-UJ_WXNaS7swTv50PIVkUTvfUlPmIj5qJaSjSw7kY1MDw8lRAw7ltQhNOpFUdr8KeTKBPxmJHR2lq7ATaMsrUauWjU3Z4_d6-3yF5sPRZ4QdL5r0uI7qgn1pbh14tUO-iktEy7erUhRge1b9KUkKJZUETMbxhbg5tHJnqRdXhYeVA1qOfzi9H-rcb2JLKI9-QAPMuKaYPNov7QfTNvb2riPzfQ6QsJmMTeDWZkq\" rel=\"nofollow\" target=\"_blank\">Justine.OMalley@protaratx.com<\/a><br \/>646-817-2836<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxOTQ4MiM3MzMzNzMzIzIxODk3Njg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YzY4MmU5MDEtNzM3MS00NTVhLWEyNTEtNmZlN2M5NGY4ZDAxLTEyMDEzMjEtMjAyNi0wMS0wNy1lbg==\/tiny\/Protara-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) &#8212; Protara Therapeutics, Inc.\u00a0(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced\u00a0that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 pm PT in San Francisco. A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company\u2019s website:\u00a0https:\/\/ir.protaratx.com. The webcast will be archived for a limited time following the presentation. About\u00a0Protara Therapeutics, Inc. Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara\u2019s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-924778","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) &#8212; Protara Therapeutics, Inc.\u00a0(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced\u00a0that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 pm PT in San Francisco. A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company\u2019s website:\u00a0https:\/\/ir.protaratx.com. The webcast will be archived for a limited time following the presentation. About\u00a0Protara Therapeutics, Inc. Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara\u2019s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment &hellip; Continue reading &quot;Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-07T13:27:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxOTQ4MiM3MzMzNzMzIzIxODk3Njg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference\",\"datePublished\":\"2026-01-07T13:27:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/\"},\"wordCount\":238,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxOTQ4MiM3MzMzNzMzIzIxODk3Njg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/\",\"name\":\"Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxOTQ4MiM3MzMzNzMzIzIxODk3Njg=\",\"datePublished\":\"2026-01-07T13:27:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxOTQ4MiM3MzMzNzMzIzIxODk3Njg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYxOTQ4MiM3MzMzNzMzIzIxODk3Njg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","og_description":"NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) &#8212; Protara Therapeutics, Inc.\u00a0(Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced\u00a0that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 3:45 pm PT in San Francisco. A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company\u2019s website:\u00a0https:\/\/ir.protaratx.com. The webcast will be archived for a limited time following the presentation. About\u00a0Protara Therapeutics, Inc. Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara\u2019s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment &hellip; Continue reading \"Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-07T13:27:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxOTQ4MiM3MzMzNzMzIzIxODk3Njg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference","datePublished":"2026-01-07T13:27:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/"},"wordCount":238,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxOTQ4MiM3MzMzNzMzIzIxODk3Njg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/","name":"Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxOTQ4MiM3MzMzNzMzIzIxODk3Njg=","datePublished":"2026-01-07T13:27:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxOTQ4MiM3MzMzNzMzIzIxODk3Njg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYxOTQ4MiM3MzMzNzMzIzIxODk3Njg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/protara-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/924778","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=924778"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/924778\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=924778"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=924778"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=924778"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}